Shifting Survival Horizons in Advanced Ovarian Cancer: A Conditional Survival Perspective

TL;DR

This study shows that survival chances for advanced ovarian cancer patients improve over time, offering a new way to counsel patients and plan long-term care.

Contribution

The study introduces conditional survival analysis to demonstrate how prognosis improves dynamically over time in advanced ovarian cancer patients.

Findings

Median overall survival was 4.37 years and progression-free survival was 1.70 years.

Conditional survival rates improved significantly with longer survival durations.

Approximately 11% of patients survived beyond ten years.

Abstract

Advanced-stage epithelial ovarian cancer (EOC) is one of the most fatal gynecologic malignancies, characterized by marked biological heterogeneity that makes prognostication and patient counseling particularly challenging. Traditional survival statistics fail to capture the dynamic, time-dependent nature of prognosis in this diverse population. In this two-decade real-world study involving a large cohort, we applied conditional survival (CS) analysis to evaluate how prognosis evolves as patients live longer and remain progression-free. Our findings show that survival expectations become increasingly favorable over time, reflecting the dynamic and time-dependent nature of risk. Recognizing this evolving prognosis can help clinicians tailor follow-up intensity and improve the accuracy of patient counseling. Conditional survival thus provides a more realistic, evidence-based framework for personalized survivorship planning and may help reduce uncertainty and anxiety among long-term survivors of advanced EOC.

Advanced-stage epithelial ovarian cancer (EOC) is defined by biological heterogeneity and poor outcomes, and traditional survival metrics fail to reflect the evolving nature of prognosis as patients survive longer. This study aimed to evaluate conditional survival (CS) in advanced EOC using both overall survival (OS) and progression-free survival (PFS) metrics to provide a dynamic understanding of long-term outcomes. We retrospectively analyzed 808 patients with FIGO stage III–IV EOC who underwent surgery at Baskent University Ankara Hospital between 2004 and 2024. CS estimates were calculated for additional 1- and 5-year intervals among patients who had already survived 6 months, 1, 3, or 5 years after surgery. Median OS and PFS were 4.37 and 1.70 years, respectively. Peritoneal dissemination and platinum resistance were independent predictors of poor survival. Approximately 11% of patients achieved survival beyond ten years. The 1-year CS-OS increased from 87% at 6 months to 95% at 5 years, while the 5-year CS-OS rose from 49% to 66%; corresponding CS-PFS values increased from 89% to 95% and from 44% to 62%. Conditional survival analysis underscores that prognosis in advanced ovarian cancer is not static but continually improves with time survived and sustained disease control. These insights redefine long-term outcomes and provide a modern foundation for individualized patient counseling and survivorship planning.

Figures